Aviva
PTGX icon

Aviva’s Protagonist Therapeutics PTGX Stock Holding History

Aviva’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,609
Closed -$490K – 897
2025
Q4 		$490K Sell
5,609
-2,183
-28% -$179K ﹤0.01% 776
2025
Q3 		$518K Sell
7,792
-1,643
-17% -$93.4K ﹤0.01% 724
2025
Q2 		$521K Sell
9,435
-3,765
-29% -$181K ﹤0.01% 708
2025
Q1 		$638K Sell
13,200
-1,427
-10% -$59.8K ﹤0.01% 661
2024
Q4 		$565K Buy
+14,627
New +$638K ﹤0.01% 770

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Aviva's PTGX Position: Q1 2026 in Review

Aviva sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 5,609 shares — an estimated $490K sold.

Aviva first reported a position in PTGX in Q4 2024 and held it in 5 quarters. The position peaked at $638K in Q1 2025. 320 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Aviva reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aviva sold 5,609 Protagonist Therapeutics shares in Q1 2026, an estimated $490K.
  • Aviva first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 5 quarters.
  • Aviva's Protagonist Therapeutics position peaked at $638K in Q1 2025.
  • 320 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.